Dossier assessment
Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Added benefit of ingenol mebutate is not proven
Manufacturer's dossier did not contain any relevant data for the comparison with diclofenac/hyaluronic acid gel
Additional information
Federal Joint Committee (G-BA)
20 August 2020: The G-BA’s decision of 21 February 2019 was cancelled.
G-BA documents on this decision
Project details
- Project no.
- A13-04
- Commission
- Commission awarded on 14.01.2013 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed